Structural basis of respiratory syncytial virus neutralization by motavizumab

Motavizumab is ~tenfold more potent than its predecessor, palivizumab (Synagis), the FDA-approved monoclonal antibody used to prevent respiratory syncytial virus (RSV) infection. The structure of motavizumab in complex with a 24-residue peptide corresponding to its epitope on the RSV fusion (F) glyc...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: McLellan, Jason S, Chen, Man, Kim, Albert, Yang, Yongping, Graham, Barney S, Kwong, Peter D
Format: Artigo
Sprog:Inglês
Udgivet: 2010
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3050594/
https://ncbi.nlm.nih.gov/pubmed/20098425
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nsmb.1723
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker